PMID- 24678687
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20141120
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 138
IP  - 4
DP  - 2014 Apr
TI  - Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ 
      hybridization DNA probe cocktail assay performed on cell blocks to 
      immunohistochemisty and fluorescence in situ hybridization performed on 
      histologic specimens.
PG  - 553-8
LID - 10.5858/arpa.2013-0314-SA [doi]
AB  - CONTEXT: Validation of new methodologies for determining human epidermal growth 
      factor receptor 2 gene (HER2/neu) amplification status is crucial for advancing 
      the standard of care and determining treatment for patients with primary and/or 
      metastatic breast carcinoma. OBJECTIVE: To compare results of HER2/neu gene 
      amplification status by 2-color chromogenic in situ hybridization (ISH) on cell 
      block material to HER2/neu status by immunohistochemistry (IHC) and/or 
      fluorescence in situ hybridization (FISH) in the corresponding resection specimen 
      or previous biopsy specimen. DESIGN: Formalin, thrombin, and Cellient cell blocks 
      were prepared from cytologic samples obtained from resection specimens from 27 
      patients with invasive breast carcinoma. In situ hybridization was performed on 
      cell block sections from 18 of the collected cases, on both the Ventana BenchMark 
      ULTRA and the Ventana BenchMark XT, and the HER2/neu gene amplification status 
      was determined. This was then compared to the HER2/neu status by IHC and/or FISH 
      in the resection specimen or previous biopsy specimen. RESULTS: Comparison of 
      HER2/neu status by ISH on the quantifiable cell block sections showed 100% 
      correlation with the HER2/neu status determined by IHC or FISH in the 
      corresponding histologic specimens. The results from thrombin and formalin cell 
      blocks were statistically superior to the results from Cellient cell blocks on 
      both Ventana instruments. CONCLUSIONS: While further validation and study are 
      needed, preliminary results show that the HER2/neu gene amplification status of 
      breast carcinomas can reliably be determined on thrombin and formalin cell block 
      material by using ISH. More consistent staining and better signal integrity was 
      obtained with the Ventana BenchMark ULTRA than the BenchMark XT.
FAU - Hartman, Adria K
AU  - Hartman AK
AD  - From the Department of Pathology and Genomic Medicine, The Methodist Hospital, 
      Houston, Texas, and Weill Medical College of Cornell University, New York, New 
      York.
FAU - Gorman, Blythe K
AU  - Gorman BK
FAU - Chakraborty, Subhendu
AU  - Chakraborty S
FAU - Mody, Dina R
AU  - Mody DR
FAU - Schwartz, Mary R
AU  - Schwartz MR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (DNA Probes)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - DNA Probes
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Middle Aged
MH  - Molecular Probe Techniques
MH  - Neoplasm Metastasis/genetics/pathology
MH  - Pilot Projects
MH  - Receptor, ErbB-2/genetics/metabolism
EDAT- 2014/04/01 06:00
MHDA- 2014/06/03 06:00
CRDT- 2014/04/01 06:00
PHST- 2014/04/01 06:00 [entrez]
PHST- 2014/04/01 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - 10.5858/arpa.2013-0314-SA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2014 Apr;138(4):553-8. doi: 10.5858/arpa.2013-0314-SA.